- Volumes 84-95 (2024)
-
Volumes 72-83 (2023)
-
Volume 83
Pages 1-258 (December 2023)
-
Volume 82
Pages 1-204 (November 2023)
-
Volume 81
Pages 1-188 (October 2023)
-
Volume 80
Pages 1-202 (September 2023)
-
Volume 79
Pages 1-172 (August 2023)
-
Volume 78
Pages 1-146 (July 2023)
-
Volume 77
Pages 1-152 (June 2023)
-
Volume 76
Pages 1-176 (May 2023)
-
Volume 75
Pages 1-228 (April 2023)
-
Volume 74
Pages 1-200 (March 2023)
-
Volume 73
Pages 1-138 (February 2023)
-
Volume 72
Pages 1-144 (January 2023)
-
Volume 83
-
Volumes 60-71 (2022)
-
Volume 71
Pages 1-108 (December 2022)
-
Volume 70
Pages 1-106 (November 2022)
-
Volume 69
Pages 1-122 (October 2022)
-
Volume 68
Pages 1-124 (September 2022)
-
Volume 67
Pages 1-102 (August 2022)
-
Volume 66
Pages 1-112 (July 2022)
-
Volume 65
Pages 1-138 (June 2022)
-
Volume 64
Pages 1-186 (May 2022)
-
Volume 63
Pages 1-124 (April 2022)
-
Volume 62
Pages 1-104 (March 2022)
-
Volume 61
Pages 1-120 (February 2022)
-
Volume 60
Pages 1-124 (January 2022)
-
Volume 71
- Volumes 54-59 (2021)
- Volumes 48-53 (2020)
- Volumes 42-47 (2019)
- Volumes 36-41 (2018)
- Volumes 30-35 (2017)
- Volumes 24-29 (2016)
- Volumes 18-23 (2015)
- Volumes 12-17 (2014)
- Volume 11 (2013)
- Volume 10 (2012)
- Volume 9 (2011)
- Volume 8 (2010)
- Volume 7 (2009)
- Volume 6 (2008)
- Volume 5 (2007)
- Volume 4 (2006)
- Volume 3 (2005)
- Volume 2 (2004)
- Volume 1 (2003)
• Tumor-specific prodrug nanoparticles were designed with carbon dot-drug conjugate.
• Degradable hyperbranched polymer was designed as both surfactant and gatekeeper.
• Excellent pH/reduction dual-triggered drug release behavior was achieved.
• Enhanced cytotoxicity was achieved than the free DOX.
• Fluorescence could be recovered during the drug release for imaging application.
Carbon dots (CDs) have attracted more interest in tumor theranostics, but they suffer from the rapid renal clearance due to small size and high hydrophilicity. To solve such problems, hydrophobic pH-triggered carbon dot-drug conjugate (CDs-Hy-DOX) with high doxorubicin (DOX) content of 48.23% were designed by covalent conjugation of DOX onto the CDs via acid-labile linkage with hydrazine (Hy) as bridge. Then the fluorescent traceable hybrid prodrug nanoparticles were fabricated via co-self-assembly with the CDs-Hy-DOX as pH-sensitive prodrug and a pH/reduction dual-triggered degradable hyperbranched polymer PEG-PO-Cy as polyethylene glycol (PEG)-based surfactant, as well as gatekeeper for pH/reduction dual-triggered DOX release. The hybrid prodrug nanoparticles with hydrodynamic diameter of 220 nm and DOX content of 22.99% were obtained with the optimized co-self-assembling condition. They could release 68.98% of DOX in the simulated tumor microenvironment within 3 days in a sustained release mode, with a premature drug leakage of 7.58%. After the acid-triggered DOX release from the CDs-Hy-DOX, which was accelerated by the pH/reduction dual-triggered degradation of the hyperbranched polymer, the strong fluorescence of CDs-Hy was recovered, demonstrating the promising potential in future tumor nanotheranostics.